Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

GlobeNewsWire • Jun 14, 2026

Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals

GlobeNewsWire • Jun 2, 2026

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities

Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions

GlobeNewsWire • Jun 2, 2026

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY.

GlobeNewsWire • May 22, 2026

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter       Management Hosting Conference Call at 4:30 p.m. ET Today         SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026.

GlobeNewsWire • May 7, 2026

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to a loss of $1.04 per share a year ago.

Zacks Investment Research • May 7, 2026

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 30, 2026

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics' first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly. “The European Commission's decision to approve Palsonify reflects the strength of the clinical data and marks a pivotal step toward bringing this important therapy to even more people living with acromegaly,” said Scott Struthers, Ph.D.

GlobeNewsWire • Apr 27, 2026

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

GlobeNewsWire • Apr 8, 2026